W World Corp. Stock OTC Markets

Equities

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2013	Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer	CI
2012	Pharmos Corp. Announces Management Changes	CI

Duration

Period

Style

Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer	13-01-02	CI
Pharmos Corp. Announces Management Changes	12-10-17	CI
Pharmos Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	12-07-30	CI
Pharmos Corp. Announces Successfully Completion of Proof-Of-Concept Clinical Trial Using its Compound Levotofisopam to Treat Patients with Hyperuricemia and Gout	12-05-17	CI
Pharmos Corp. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2012	12-04-16	CI
Pharmos Corp. Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout	12-04-05	CI
Pharmos Corp. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011	12-02-17	CI

W World Corp. is a United States-based company. The Company has no operation nor generated any revenue.

Sector